With an FDA approval, it would be the first new class of oral antibiotics for uncomplicated urinary tract infections (uUTI) in over 20 years.
During the ongoing European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GSK presented its data from the pivotal EAGLE-2 and EAGLE-3 phase 3 trials for its investigational antibiotic, gepotidacin, for uUTI.
The trials showed gepotidacin met primary endpoint of non-inferiority to nitrofurantoin; and EAGLE-3 demonstrated statistical superiority.
“These results are a significant step forward in an area that has seen very little innovation for decades. Gepotidacin is the first antibiotic to meet contemporary regulatory criteria, which set a high threshold for the efficacy of treatments in uncomplicated urinary tract infections,” Florian Martin Erich Wagenlehner, MD, principal Investigator for the EAGLE-2 phase 3 trial, said in a statement. “Gepotidacin has the potential to offer healthcare professionals another oral option to treat this common community infection.”
This is a first-in-class oral antibiotic with a novel mechanism of action for uUTI in female adults and adolescents. And if it is approved, it would be the first antibiotic in a new class to get the FDA nod for this indication in over 20 years.
Results
The EAGLE-2 and EAGLE-3 phase 3 trials were near-identical global, randomized, parallel-group, double-blind, non-inferiority (10% margin) trials comparing the efficacy and safety of oral gepotidacin to nitrofurantoin for the treatment of uUTI. A total of 3136 patients were enrolled across both trials.
EAGLE-2 (non-inferiority uUTI trial) compared the efficacy and safety of gepotidacin (1500mg administered orally twice daily for five days) to nitrofurantoin (100mg administered orally twice daily for five days). The trial duration for participants was approximately 28 days.
The primary endpoint was the combined clinical and microbiological response at the ToC visit (days 10-13) in patients with qualifying uropathogens susceptible to nitrofurantoin. EAGLE-3 (non-inferiority uUTI trial) compared the efficacy and safety of gepotidacin (1500mg administered orally twice daily for five days) to nitrofurantoin (100mg administered orally twice daily for five days). The trial duration for participants was approximately 28 days. The primary endpoint was the combined clinical and microbiological response at the ToC visit (days 10-13) in patients with qualifying uropathogens susceptible to nitrofurantoin.
Gepotidacin’s Specifics
This antibiotic, developed by GSK, is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different Type II topoisomerase enzymes. This provides activity against most strains of target uropathogens, such as E coli and Staphylococcus saprophyticus, including isolates resistant to current antibiotics. Furthermore, due to the well-balanced inhibition of two enzymes, mutations in both enzymes are needed to significantly affect susceptibility to gepotidacin.
Next Steps
GSK is planning an FDA submission for gepotidacin in this quarter, and believes this therapy could be a welcome antibiotic addition for this indication. “We believe that gepotidacin, if approved, will offer a much-needed additional oral treatment option for patients at risk of treatment failure associated with resistance or recurrence of uUTI,” Chris Corsico, MD, MPH, senior vice president, Development, GSK, said in a statement. “We are committed to working with global regulators to bring this new antibiotic to patients as quickly as possible.”
This article was published by our sister publication Contagion Live.
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial
March 19th 2024Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
FDA approves enmetazobactam for treatment of cUTIs
February 23rd 2024Enmetazobactam (Exblifep; Orchid Pharma) gains FDA approval for treating complicated urinary tract infections in adults after demonstrating superiority over piperacillin-tazobactam in clinical cure and microbiological eradication in a global phase 3 trial.
Read More